



FOR IMMEDIATE RELEASE

AMOÉBA ANNOUNCES RECEIPT OF THE EVALUATION REPORT FROM THE FRENCH COMPETENT AUTHORITY, ANSES

Lyon, March 16th, 2017 - AMOÉBA (FR0011051598 - AMEBA), manufacturer of a biological biocide capable of eliminating the risk of waterborne bacteria, announces receipt of the evaluation report for the active substance of the BIOMEBA biocidal product, *Willaertia magna C2c Maky*.

All the required regulatory studies for a micro-organism application have demonstrated the absence of toxicity to human health, animal health and environment, and have validated the industrial efficacy of the product.

However, the French regulatory body, ANSES, considers that it cannot recommend the approval of the *Willaertia magna C2c Maky* active substance in view of the observations that it wishes to have clarified by experts at European level.

The application for marketing authorization has been transmitted to the European Chemicals Agency (ECHA) in order to initiate the peer review of the evaluation by the Member States competent authorities, which will take on the evaluation from now on, in concertation with AMOÉBA. The final opinion will be made after examination by the Working Group planned in September 2017, followed by the Biocidal Product Committee to be held in December 2017 that will conclude the evaluation.

During this peer review period, the company will benefit from a newly created working group of European experts on micro-organism active substances.

The absence of positive recommendation does not allow the company to submit a provisional marketing authorization application in France nor in the other Member States. However, the company indicates to have sufficient funds to continue to operate, pending Europe's final decision in December 2017.



« The absence of positive recommendation from the French authority, ANSES, is frustrating considering the work carried out by our teams and the quality of the scientific data submitted. The European process will allow us to promote elements that have not been considered during the initial evaluation nor in the comments' phase. Lastly, the recent creation of a group of experts on micro-organism demonstrates well the difficulty to assess a biocidal microorganism in a sector dominated by chemical substances”, stated **Fabrice PLASSON, President of AMOEBA's Board of Directors.**



About AMOEBA:

AMOEBEA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.). This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector and complies with the new regulations in terms of chemical emissions into the environment. In a worldwide market for chemical biocides estimated to be worth EUR 21 bn⁽¹⁾, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT), estimated to be worth EUR 1.7 bn⁽²⁾. AMOEBA is continuing with the regulatory procedures necessary to obtain MA for all European countries for the “Air Cooled Towers” application. Based in Lyon-Chassieu (France), AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC® Small index on 21st September 2015. For more information: www.amoeba-biocide.com.

(1) : Sources combined by Amoeba from water treatment agencies, Freedonia, Eurostat and MarketsandMarkets

(2) : Amoeba data combined from the following sources: DRIRE 2013, Eurostat, ARHIA 2013

Contacts :

Amoéba

Nathalie COMBROUSSE

Responsable Marketing Communication

Tel : +33 (0)4 81 09 18 15

nathalie.combrousse@amoeba-biocide.com

Actifin

Ghislaine GASPARETTO

Communication financière

Tel : +33 (0)1 56 88 11 11

ggasparetto@actifin.fr